Institution
University of Modena and Reggio Emilia
Education•Modena, Italy•
About: University of Modena and Reggio Emilia is a education organization based out in Modena, Italy. It is known for research contribution in the topics: Population & Transplantation. The organization has 8179 authors who have published 22418 publications receiving 671337 citations. The organization is also known as: Università degli Studi di Modena e Reggio Emilia & Universita degli Studi di Modena e Reggio Emilia.
Topics: Population, Transplantation, Stem cell, Cancer, Breast cancer
Papers published on a yearly basis
Papers
More filters
••
University of Wisconsin-Madison1, Ludwig Maximilian University of Munich2, Hannover Medical School3, French Institute of Health and Medical Research4, British Heart Foundation5, RWTH Aachen University6, Saarland University7, University of Glasgow8, Charité9, University of Melbourne10, University of Alabama at Birmingham11, Thermo Fisher Scientific12, University College Dublin13, Harvard University14, Joslin Diabetes Center15, University of Modena and Reggio Emilia16, University of Picardie Jules Verne17, University of Regensburg18, The Heart Research Institute19, Leipzig University20, Department of Urology, University of Virginia21, Mahidol University22
TL;DR: The establishment of a reproducible, high resolution method for peptidome analysis of naturally occurring human urinary peptides and proteins, ranging from 800 to 17,000 Da, using samples from 3,600 individuals analyzed by capillary electrophoresis coupled to MS is reported.
447 citations
••
University of Marburg1, Temple University2, NewYork–Presbyterian Hospital3, University of Texas Health Science Center at San Antonio4, National Institutes of Health5, McGill University Health Centre6, Brigham and Women's Hospital7, Guangzhou Medical University8, Katholieke Universiteit Leuven9, University of Modena and Reggio Emilia10, Flinders University11, Royal Devon and Exeter Hospital12, University of the Republic13, Hokkaido University14, Paris Descartes University15, University of Barcelona16, University of British Columbia17, University of Manchester18, University of Birmingham19
TL;DR: The assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation, and the importance of comorbid conditions in managing COPD is reviewed.
Abstract: This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: 1) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed.
444 citations
••
TL;DR: Some recent findings concerning the structure and function of native nAChRs are reviewed, focusing on the subtypes identified in the mesostriatal and habenulo-interpeduncular pathways, two systems involved in nicotine reinforcement and withdrawal.
444 citations
••
TL;DR: Experimental evidence obtained in combined hippocampus-entorhinal cortex slices perfused with artificial cerebrospinal fluid containing convulsants or nominally zero Mg(2+), in order to produce epileptiform synchronization indicates that these changes in network interactions, along with other mechanisms of synaptic plasticity can confer to the epileptic, damaged limbic system, the ability to produce recurrent limbic seizures.
442 citations
••
TL;DR: Compared with placebo, BLF supplementation alone or in combination with LGG reduced the incidence of a first episode of late-onset sepsis in VLBW neonates.
Abstract: Context Sepsis is a common and severe complication in premature neonates, particularly those with very low birth weight (VLBW) ( Objective To establish whether bovine lactoferrin (BLF), alone or in combination with LGG, reduces the incidence of late-onset sepsis in VLBW neonates. Design, Setting, and Patients Prospective, multicenter, double-blind, placebo-controlled, randomized trial conducted in 11 Italian tertiary neonatal intensive care units. Patients were 472 VLBW infants enrolled from October 1, 2007, through July 31, 2008, and assessed until discharge for development of sepsis. Intervention Infants were randomly assigned to receive orally administered BLF (100 mg/d) alone (n = 153), BLF plus LGG (6 × 10 9 colony-forming units/d) (n = 151), or placebo (n = 168) from birth until day 30 of life (day 45 for neonates Main Outcome Measure First episode of late-onset sepsis, ie, sepsis occurring more than 72 hours after birth with isolation of any pathogen from blood or from peritoneal or cerebrospinal fluid. Results Demographic, clinical, and management characteristics of the 3 groups were similar, including type of feeding and intake of maternal milk. Incidence of late-onset sepsis was significantly lower in the BLF and BLF plus LGG groups (9/153 [5.9%] and 7/151 [4.6%], respectively) than in the control group receiving placebo (29/168 [17.3%]) (risk ratio, 0.34; 95% confidence interval, 0.17-0.70; P = .002 for BLF vs control and risk ratio, 0.27; 95% confidence interval, 0.12-0.60; P Conclusion Compared with placebo, BLF supplementation alone or in combination with LGG reduced the incidence of a first episode of late-onset sepsis in VLBW neonates. Trial Registration isrctn.org Identifier: ISRCTN53107700
441 citations
Authors
Showing all 8322 results
Name | H-index | Papers | Citations |
---|---|---|---|
Carlo M. Croce | 198 | 1135 | 189007 |
Gregory Y.H. Lip | 169 | 3159 | 171742 |
Geoffrey Burnstock | 141 | 1488 | 99525 |
Peter M. Rothwell | 134 | 779 | 67382 |
Claudio Franceschi | 120 | 856 | 59868 |
Lorenzo Galluzzi | 118 | 477 | 71436 |
Leonardo M. Fabbri | 109 | 566 | 60838 |
David N. Reinhoudt | 107 | 1082 | 48814 |
Stefano Pileri | 100 | 635 | 43369 |
Andrea Bizzeti | 99 | 1168 | 46880 |
Brian K. Shoichet | 98 | 281 | 40313 |
Dante Gatteschi | 97 | 727 | 48729 |
Roberta Sessoli | 95 | 424 | 41458 |
Thomas A. Buchholz | 93 | 494 | 33409 |
Pier Luigi Zinzani | 92 | 857 | 35476 |